Results 31 to 40 of about 8,529 (239)

Guide to development of compound files for PBPK modeling in the Simcyp population‐based simulator

CPT: Pharmacometrics & Systems Pharmacology, 2022
The Simcyp Simulator is a software platform for population physiologically‐based pharmacokinetic (PBPK) modeling and simulation. It links in vitro data to in vivo absorption, distribution, metabolism, excretion and pharmacokinetic/pharmacodynamic ...
Udoamaka Ezuruike, Mian Zhang, Amita Pansari, Mailys De Sousa Mendes, Xian Pan, Sibylle Neuhoff, Iain Gardner   +6 more
doaj   +1 more source

Predicting the correct dose in children: Role of computational Pediatric Physiological‐based pharmacokinetics modeling tools

CPT: Pharmacometrics & Systems Pharmacology, 2023
The pharmacokinetics (PKs) and safety of medications in particular groups can be predicted using the physiologically‐based pharmacokinetic (PBPK) model.
Xu Zhou, Jiening Dun, Xiao Chen, Bai Xiang, Yunjie Dang, Deying Cao   +5 more
doaj   +1 more source

Indocyanine green physiological based pharmacokinetics model (PBPK)

, 2021
This repository provides the indocyanine green physiological based pharmacokinetics model (PBPK) described in Prediction of survival after partial hepatectomy using a physiologically based pharmacokinetic model of indocyanine green liver function ...
König, Matthias, Köller, Adrian
core   +1 more source

Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients

Pharmaceutics, 2020
Fentanyl is widely used for analgesia, sedation, and anesthesia both in adult and pediatric populations. Yet, only few pharmacokinetic studies of fentanyl in pediatrics exist as conducting clinical trials in this population is especially challenging ...
Lukas Kovar, Andreas Weber, Michael Zemlin, Yvonne Kohl, Robert Bals, Bernd Meibohm, Dominik Selzer, Thorsten Lehr   +7 more
doaj   +1 more source

Physiologically Based Pharmacokinetic Modeling of Cefadroxil in Mouse, Rat, and Human to Predict Concentration–Time Profile at Infected Tissue

Frontiers in Pharmacology, 2021
The aim of this study was to develop physiologically based pharmacokinetic (PBPK) models capable of simulating cefadroxil concentrations in plasma and tissues in mouse, rat, and human.
Zhongxia Tan, Youxi Zhang, Chao Wang, Le Sun   +3 more
doaj   +1 more source

Physiologically-based pharmacokinetic modeling for optimal dosage prediction of olaparib when co-administered with CYP3A4 modulators and in patients with hepatic/renal impairment

Scientific Reports, 2023
This study aimed to develop a physiologically-based pharmacokinetic (PBPK) model to predict the maximum plasma concentration (Cmax) and trough concentration (Ctrough) at steady-state of olaparib (OLA) in Caucasian, Japanese and Chinese.
Dongmei Gao, Guopeng Wang, Honghai Wu, Jiawei Ren   +3 more
doaj   +1 more source

A Workflow for Global Sensitivity Analysis of PBPK Models [PDF]

Frontiers in Pharmacology, 2011
Physiologically based pharmacokinetic (PBPK) models have a potentially significant role in the development of a reliable predictive toxicity testing strategy. The structure of PBPK models are ideal frameworks into which disparate in vitro and in vivo data can be integrated and utilized to translate information generated, using alternative to animal ...
McNally, Kevin, Cotton, Richard, Loizou, George D.   +2 more
openaire   +3 more sources

Developing a Physiologically-Based Pharmacokinetic Model Knowledgebase in Support of Provisional Model Construction.

PLoS Computational Biology, 2016
Developing physiologically-based pharmacokinetic (PBPK) models for chemicals can be resource-intensive, as neither chemical-specific parameters nor in vivo pharmacokinetic data are easily available for model construction.
Jingtao Lu, Michael-Rock Goldsmith, Christopher M Grulke, Daniel T Chang, Raina D Brooks, Jeremy A Leonard, Martin B Phillips, Ethan D Hypes, Matthew J Fair, Rogelio Tornero-Velez, Jeffre Johnson, Curtis C Dary, Yu-Mei Tan   +12 more
doaj   +1 more source

Development of a multi-route physiologically based pharmacokinetic (PBPK) model for nanomaterials: a comparison between a traditional versus a new route-specific approach using gold nanoparticles in rats

Particle and Fibre Toxicology, 2022
Background Physiologically based pharmacokinetic (PBPK) modeling is an important tool in predicting target organ dosimetry and risk assessment of nanoparticles (NPs).
Wei-Chun Chou, Yi-Hsien Cheng, Jim E. Riviere, Nancy A. Monteiro-Riviere, Wolfgang G. Kreyling, Zhoumeng Lin   +5 more
doaj   +1 more source

A new "old" model: PBPK

, 2022
A new "old" model: PBPK.
L. Palazzolo
core